Last reviewed · How we verify
Treatment of non-muscle invasive bladder cancer (NMIBC) with high-risk tumor — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Tice Bcg | bcg | Pfizer | Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC] | BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages. |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 1 drug in Treatment of non-muscle invasive bladder cancer (NMIBC) with high-risk tumor
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Treatment of non-muscle invasive bladder cancer (NMIBC) with high-risk tumor:
- Treatment of non-muscle invasive bladder cancer (NMIBC) with high-risk tumor treatment updates — RSS
- Treatment of non-muscle invasive bladder cancer (NMIBC) with high-risk tumor treatment updates — Atom
- Treatment of non-muscle invasive bladder cancer (NMIBC) with high-risk tumor treatment updates — JSON
Cite this brief
Drug Landscape (2026). Treatment of non-muscle invasive bladder cancer (NMIBC) with high-risk tumor — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/treatment-of-non-muscle-invasive-bladder-cancer-nmibc-with-high-risk-tumor. Accessed 2026-06-10.
Related
- Treatment of non-muscle invasive bladder cancer (NMIBC) with high-risk tumor full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing